LY2090314 - ≥98%, high purity , CAS No.603288-22-8, Inhibitor of glycogen synthase kinase 3 beta

Item Number

L126079

Grouped product items
SKU	Size	Availability	Price
L126079-5mg	5mg	Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!	$117.90
L126079-25mg	25mg	Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!	$531.90
L126079-100mg	100mg	Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!	$870.90

View related series

Basic Description

Synonyms	LY2090314\|603288-22-8\|LY-2090314\|Kinome_3681\|LY 2090314\|3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione\|CHEMBL362558\|822M3GYM67\|UNII-822M3GYM67\|SCHEMBL633455\|
Specifications & Purity	Moligand™, ≥98%
Biochemical and Physiological Mechanisms	LY2090314 is a potent and selective ATP-competitive inhibitor of Glycogen synthase kinase-3 (GSK-3) currently in clinical trials for cancer therapy. LY2090314 has IC50 values of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β, respectively.
Storage Temp	Store at -20°C
Shipped In	Ice chest + Ice pads
Grade	Moligand™
Action Type	INHIBITOR
Mechanism of action	Inhibitor of glycogen synthase kinase 3 beta
Note	卖完停产，不再备货
Product Description	LY2090314 is a potent GSK-3 inhibitor for GSK-3α/β with IC50 of 1.5 nM/0.9 nM; may improve the efficacy of platinum-based chemotherapy regimens.

Names and Identifiers

IUPAC Name	3-[6-fluoro-10-(piperidine-1-carbonyl)-1,10-diazatricyclo[6.4.1.04,13]trideca-2,4,6,8(13)-tetraen-3-yl]-4-imidazo[1,2-a]pyridin-3-ylpyrrole-2,5-dione
INCHI	InChI=1S/C28H25FN6O3/c29-18-12-17-15-34(28(38)32-7-3-1-4-8-32)11-10-33-16-20(19(13-18)25(17)33)23-24(27(37)31-26(23)36)21-14-30-22-6-2-5-9-35(21)22/h2,5-6,9,12-14,16H,1,3-4,7-8,10-11,15H2,(H,31,36,37)
InChi Key	HRJWTAWVFDCTGO-UHFFFAOYSA-N
Canonical SMILES	C1CCN(CC1)C(=O)N2CCN3C=C(C4=CC(=CC(=C43)C2)F)C5=C(C(=O)NC5=O)C6=CN=C7N6C=CC=C7
Isomeric SMILES	C1CCN(CC1)C(=O)N2CCN3C=C(C4=CC(=CC(=C43)C2)F)C5=C(C(=O)NC5=O)C6=CN=C7N6C=CC=C7
Alternate CAS	603288-22-8
PubChem CID	10029385
MeSH Entry Terms	3-(9-fluoro-2-(piperidin-1-ylcarbonyl)-1,2,3,4-tetrahydro(1,4)diazepino(6,7,1-hi)indol-7-yl)-4-imidazo(1,2-a)pyridin-3-yl-1H-pyrrole-2,5-dione;LY2090314
Molecular Weight	512.53

Certificates

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

1 results found

Lot Number	Certificate Type	Date	Item
E1708009	Certificate of Analysis	Dec 08, 2022	L126079

References

1. Doble BW, Woodgett JR. (2003) GSK-3: tricks of the trade for a multi-tasking kinase.. J Cell Sci, 116 (Pt 7): (1175-86). [PMID:12615961]
2. Engler TA, Henry JR, Malhotra S, Cunningham B, Furness K, Brozinick J, Burkholder TP, Clay MP, Clayton J, Diefenbacher C et al.. (2004) Substituted 3-imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3.. J Med Chem, 47 (16): (3934-7). [PMID:15267232]
3. Jope RS, Yuskaitis CJ, Beurel E. (2007) Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics.. Neurochem Res, 32 (4-5): (577-95). [PMID:16944320]
4. Vadivelan S, Sinha BN, Tajne S, Jagarlapudi SA. (2009) Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models.. Eur J Med Chem, 44 (6): (2361-71). [PMID:18929433]

Solution Calculators

Determine the necessary mass, volume, or concentration for preparing a solution.

Determine the dilution needed to prepare a stock solution.

Basic Description